BMS 493

SIGMA/B6688 - ≥98% (HPLC)

Synonym: (E)-4-[2-[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)naphthalen-2-yl]ethen-1-yl]benzoic acid; 4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(phenylethynyl)-2-naphthalenyl]ethenyl]-benzoic acid; BMS204, 493

CAS Number: 215030-90-3
Empirical Formula (Hill Notation): C₂₉H₂₄O₂
Molecular Weight: 404.50
MDL Number: MFCD17215944
Linear Formula: C₂₉H₂₄O₂
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-B6688-5MG	5 mg	$212.00 1/EA	Add To Favorites
45-B6688-25MG	25 mg	$835.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	light yellow to yellow
form	powder
InChI	1S/C29H24O2/c1-29(2)19-18-24(14-10-21-6-4-3-5-7-21)26-20-23(13-17-27(26)29)9-8-22-11-15-25(16-12-22)28(30)31/h3-9,11-13,15-18,20H,19H2,1-2H3,(H,30,31)/b9-8+
InChI key	YCADIXLLWMXYKW-CMDGGOBGSA-N
originator	Bristol-Myers Squibb
Quality Level	100
SMILES string	CC1(C)CC=C(C#Cc2ccccc2)c3cc(C=Cc4ccc(cc4)C(O)=O)ccc13
solubility	DMSO: ≥20 mg/mL
storage temp.	2-8°C

Application:	BMS 493 has been used: • as an inhibitor for the dietary and pharmacologic manipulation of retinoic acid (RA) activity in vivo and in vitro • for human induced pluripotent stem cells (iPSCs) culture and ventricular cardiomyocytes (VCMs) differentiation • to inhibit retinoic acid (RA) signaling in explants • as a retinoic acid receptor (RAR) inhibitor for the induction of synaptonemal complex protein 3 (SCP3) and ATP-dependent RNA helicase (DDX4) in primordial germ cells (PGCs)
Biochem/physiol Actions:	BMS 493 is an inverse pan-RAR agonist.
Biochem/physiol Actions:	BMS 493 is an inverse pan-RAR agonist. Retinoic acid receptors (RARs) are ligand-dependent transcription factors that control a number of physiological processes. RARs exert their functions by regulating gene networks controlling cell growth, differentiation, survival, and death.
Features and Benefits:	This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm .
Features and Benefits:	This compound is featured on the Nuclear Receptors (Non-Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here .
Features and Benefits:	This compound was developed by Bristol-Myers Squibb . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
General description:	BMS 493 inhibits the formation of neuritic processes and plasmenyethanolamine -phospholipase A2 (PLA2) activity.
Packaging:	5, 25 mg in glass bottle

Hazard statements	H413
RIDADR	NONH for all modes of transport
WGK Germany	WGK 2
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	2-8°C
UNSPSC	12352200

To Order From a Quote